Cancer antigen peptide formulations

Details Cancer antigen peptide formulations Cancer antigen peptide formulations

2008-03-11

2008-03-11

Tsang, Cecilia J. (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C514S002600

Reexamination Certificate

active

10527692

ABSTRACT:
Cancer antigen peptides derived from WT1 which have an in vivo efficacy, particularly a clinical usefulness, and cancer vaccines as dosage forms suitable for said cancer antigen peptides, are provided.The invention relates to water-in-oil emulsions which comprise as an effective ingredient either one or both of peptides selected from the group consisting of a peptide having an amino acid sequence of Cys Met Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 2), and a peptide having an amino acid sequence of Cys Tyr Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 3), as well as processes for preparation of said emulsion.

REFERENCES:
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6277832 (2001-08-01), Sugiyama et al.
patent: 2003/0082194 (2003-05-01), Gaiger et al.
patent: 2003/0092656 (2003-05-01), Sugiyama
patent: 2004/0097703 (2004-05-01), Sugiyama
patent: 2004/0247609 (2004-12-01), Sugiyama
patent: 2005/0002951 (2005-01-01), Sugiyama et al.
patent: 2005/0266014 (2005-12-01), Sugiyama et al.
patent: 1 103 564 (2001-05-01), None
patent: 1 371 664 (2003-12-01), None
patent: WO-00/06602 (2000-02-01), None
patent: WO-00/18795 (2000-04-01), None
patent: WO-00/26249 (2000-05-01), None
patent: WO-02/079253 (2002-10-01), None
Cancer Prevention Overview (PDQ), Health Professional Version (on-line publication, www.cancer.gov/cancertopics/pdq/prevention/overview/healthProfessional/. Natiional Cancer Institute, U.S. National Institutes of Health. Last modified Mar. 2, 2007. pp. 1-5.
NCI Drug Dictionary. HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine. http://www.cancer.gov/Templates/drugdictionary.aspx?cdrid=433196&page=1&print=1.
U.S. Appl. No. 10/527,692, filed Mar. 11, 2005, Sugiyama.
U.S. Appl. No. 10/562,486, filed Dec. 27, 2005, Sugiyama.
U.S. Appl. No. 11/322,245, filed Jan. 3, 2006, Sugiyama, et al.
U.S. Appl. No. 09/744,815, filed Jan. 30, 2001, Sugiyama, et al.
U.S. Appl. No. 10/517,600, filed Dec. 13, 2004, Sugiyama, et al.
U.S. Appl. No. 10/528,360, filed Mar. 18, 2005, Sugiyama, et al.
U.S. Appl. No. 11/196,452, filed Aug. 4, 2005, Sugiyama, et al.
U.S. Appl. No. 10/541,821, filed Jul. 11, 2005, Sugiyama, et al.
Rosenberg, Immunity, vol. 10, pp. 281-287 (Mar. 1999).
Bakker et al., The Journal of Experimental Medicine, vol. 179, pp. 1005-1009 (Mar. 1994).
Kawakami et al., Proc. Natl. Acad. Sci. USA, vol. 91, pp. 3515-3519 (Apr. 1994).
Brichard et al., J. Exp. Med., vol. 178, pp. 489-495 (Aug. 1993).
Fisk et al., J. Exp. Med., vol. 181, pp. 2109-2117 (Jun. 1995).
Tsang et al., Journal of the National Cancer Institute, vol. 87, No. 13, pp. 982-990 (Jul. 5, 1995).
Correale et al., Journal of the National Cancer Institute, vol. 89, No. 4, pp. 293-300 (Feb. 19, 1997).
Melief et al., Cur. Opin. Immunol, vol. 5, pp. 709-713 (1993).
Pardoll, Cur. Opin. Immunol, vol. 5, pp. 719-725 (1993).
Nanda et al., Cell, vol. 82, pp. 13-17 (Jul. 14, 1995).
Melief et al., Immunological Reviews, No. 146, pp. 167-177 (1995).
Gessler et al., Nature, vol. 343, pp. 774-778 (Feb. 22, 1990).
Call et al., Cell, vol. 60, pp. 509-520 (Feb. 9, 1990).
Oka et al., The Journal of Immunology, vol. 164, pp. 1873-1880 (2000).
Tsuboi et al., Journal of Clinical Immunology, vol. 20, No. 3, pp. 195-202 (2000).

Affiliated with

Also associated with

Rating

Cancer antigen peptide formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer antigen peptide formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer antigen peptide formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3909000